title: The management of locally advanced prostate cancer.
abstract: The current management of locally advanced prostate cancer generally involves treatment with radiotherapy, hormone therapy or a combination of both. Of particular importance when choosing the type and duration of treatment is the patient's risk category, which predicts the risk of subclinical metastases based on prostate-specific antigen level, Gleason score and tumor stage. A breakout group at the PROstart 2002 workshop, charged with discussing this topic, concluded that hormone therapy is a recommended component of disease management and may improve survival, and that radiotherapy should be combined with neoadjuvant and or adjuvant hormone therapy.
authors.affiliation: Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 19107-5097, USA. richard.valicenti@mail.tju.edu
authors.forename: R K
authors.initials: RK
authors.lastname: Valicenti
mesh_terms: D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000401:mortality / Q000628:therapy*